Your browser doesn't support javascript.
loading
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria, Rodabe N; Postow, Michael; Burton, Elizabeth M; Tetzlaff, Michael T; Ross, Merrick I; Torres-Cabala, Carlos; Glitza, Isabella C; Duan, Fei; Milton, Denái R; Busam, Klaus; Simpson, Lauren; McQuade, Jennifer L; Wong, Michael K; Gershenwald, Jeffrey E; Lee, Jeffrey E; Goepfert, Ryan P; Keung, Emily Z; Fisher, Sarah B; Betof-Warner, Allison; Shoushtari, Alexander N; Callahan, Margaret; Coit, Daniel; Bartlett, Edmund K; Bello, Danielle; Momtaz, Parisa; Nicholas, Courtney; Gu, Aidi; Zhang, Xuejun; Korivi, Brinda Rao; Patnana, Madhavi; Patel, Sapna P; Diab, Adi; Lucci, Anthony; Prieto, Victor G; Davies, Michael A; Allison, James P; Sharma, Padmanee; Wargo, Jennifer A; Ariyan, Charlotte; Tawbi, Hussein A.
Afiliação
  • Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rnamaria@mdanderson.org.
  • Postow M; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Burton EM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tetzlaff MT; Department of Pathology, The University of California San Francisco, San Francisco, CA, USA.
  • Ross MI; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Torres-Cabala C; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Duan F; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Busam K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Simpson L; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Goepfert RP; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Fisher SB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Betof-Warner A; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Shoushtari AN; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Callahan M; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Coit D; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bartlett EK; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bello D; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Momtaz P; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Nicholas C; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gu A; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang X; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Korivi BR; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patnana M; Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lucci A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Prieto VG; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
  • Ariyan C; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nature ; 615(7953): E23, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36894629
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article